ASCO GI 2016

Panitumumab in Wild-Type KRAS and RAS Metastatic Colorectal Cancer

Results from an open-label, randomized phase 3 trial evaluating the effects of panitumumab plus best supportive care versus best supportive care alone in chemorefractory, wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer.

BBI608/FOLFIRI ± Bevacizumab in Advanced Colorectal Cancer

Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 in combination with FOLFIRI ± bevacizumab in patients with advanced colorectal cancer.

NEO-102, an Anti-MUC5AC Monoclonal Antibody, in Chemotherapy-Refractory Metastatic Colorectal Cancer

Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer.

STEAM—Sequential versus Concurrent FOLFOXIRI/Bevacizumab in Metastatic Colorectal Cancer

Results from STEAM, an open-label, randomized, phase 2 study of sequential versus concurrent FOLFOXIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer.

Avelumab in Advanced Gastric or Gastroesophageal Cancer

Results from the phase 1b JAVELIN study of the anti–PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression.

Nivolumab Monotherapy in Advanced Gastroesophageal or Gastric Cancer

Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer.

Pembrolizumab in PD-L1+ Advanced Esophageal Carcinoma

Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma.

The Role of the mTOR Pathway in Cancer Stem Cells in Esophageal Cancer

Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer.

Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Results from RAINBOW, a randomized phase 3 trial of the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Treating Gastric Cancer by Targeting Notch and wnt-Beta-Catenin Cancer Stem-Cell Pathways

An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a γ-secretase inhibitor would be effective in treating patients with gastric cancer.